| review article | Q7318358 |
| scholarly article | Q13442814 |
| P356 | DOI | 10.1586/ERV.09.127 |
| P698 | PubMed publication ID | 19943764 |
| P2093 | author name string | Edwin V Oaks | |
| Robert W Kaminski | |||
| P2860 | cites work | Optimization of virulence functions through glucosylation of Shigella LPS. | Q45282739 |
| Development and evaluation of a Shigella flexneri 2a and S. sonnei bivalent invasin complex (Invaplex) vaccine | Q46938617 | ||
| Inoculum size in shigellosis and implications for expected mode of transmission | Q47172816 | ||
| The ShiA protein encoded by the Shigella flexneri SHI-2 pathogenicity island attenuates inflammation | Q47579678 | ||
| Immunogenicity and protective efficacy offered by a ribosomal-based vaccine from Shigella flexneri 2a. | Q51975208 | ||
| A role for Nod-like receptors in autophagy induced by Shigella infection. | Q53522247 | ||
| Vaccine potential for inactivated shigellae. | Q53581992 | ||
| Double-blind vaccine-controlled randomised efficacy trial of an investigational Shigella sonnei conjugate vaccine in young adults. | Q54572055 | ||
| Differential regulation of caspase-1 activation, pyroptosis, and autophagy via Ipaf and ASC in Shigella-infected macrophages | Q21131607 | ||
| Shigella flexneri type III secretion system effectors OspB and OspF target the nucleus to downregulate the host inflammatory response via interactions with retinoblastoma protein | Q24315859 | ||
| IpaB mediates macrophage apoptosis induced by Shigella flexneri | Q28254424 | ||
| Structural organization of the needle complex of the type III secretion apparatus of Shigella flexneri | Q28258916 | ||
| Shigella-induced apoptosis is dependent on caspase-1 which binds to IpaB | Q28289989 | ||
| Protein conjugates of synthetic saccharides elicit higher levels of serum IgG lipopolysaccharide antibodies in mice than do those of the O-specific polysaccharide from Shigella dysenteriae type 1 | Q28343287 | ||
| Identification of chromosomal Shigella flexneri genes induced by the eukaryotic intracellular environment | Q30836926 | ||
| Toward a better understanding of the basis of the molecular mimicry of polysaccharide antigens by peptides: the example of Shigella flexneri 5a. | Q33226009 | ||
| Dr. Kiyoshi Shiga: discoverer of the dysentery bacillus | Q33877398 | ||
| The tripartite type III secreton of Shigella flexneri inserts IpaB and IpaC into host membranes | Q33878820 | ||
| Clostridium difficile recombinant toxin A repeating units as a carrier protein for conjugate vaccines: studies of pneumococcal type 14, Escherichia coli K1, and Shigella flexneri type 2a polysaccharides in mice | Q34003957 | ||
| Safety and immunogenicity of improved Shigella O-specific polysaccharide-protein conjugate vaccines in adults in Israel | Q34006223 | ||
| Safety and immunogenicity of a proteosome-Shigella flexneri 2a lipopolysaccharide vaccine administered intranasally to healthy adults | Q34008338 | ||
| The Shigella flexneri effector OspG interferes with innate immune responses by targeting ubiquitin-conjugating enzymes | Q34048081 | ||
| Shigella enterotoxin 1: an enterotoxin of Shigella flexneri 2a active in rabbit small intestine in vivo and in vitro | Q34224319 | ||
| Safety and immunogenicity of Escherichia coli O157 O-specific polysaccharide conjugate vaccine in 2-5-year-old children | Q34486402 | ||
| Mucosal adjuvant properties of the Shigella invasin complex | Q34601845 | ||
| Hypothesis for vaccine development: protective immunity to enteric diseases caused by nontyphoidal salmonellae and shigellae may be conferred by serum IgG antibodies to the O-specific polysaccharide of their lipopolysaccharides | Q35335585 | ||
| O-specific [corrected] polysaccharide conjugate vaccine-induced [corrected] antibodies prevent invasion of Shigella into Caco-2 cells and may be curative | Q35844488 | ||
| IcsA surface presentation in Shigella flexneri requires the periplasmic chaperones DegP, Skp, and SurA. | Q35949250 | ||
| Effect of the nonreducing end of Shigella dysenteriae type 1 O-specific oligosaccharides on their immunogenicity as conjugates in mice | Q35955978 | ||
| Bacterial ghosts--biological particles as delivery systems for antigens, nucleic acids and drugs | Q35961206 | ||
| Anaerobic regulation of Shigella flexneri virulence: ArcA regulates Fur and iron acquisition genes | Q36098452 | ||
| Considerations for development of whole cell bacterial vaccines to prevent diarrheal diseases in children in developing countries | Q36101210 | ||
| Molecular pathogenesis of Shigella spp.: controlling host cell signaling, invasion, and death by type III secretion. | Q36422508 | ||
| Live-attenuated Shigella vaccines | Q36689023 | ||
| Immunological evidence for functional rather than structural mimicry by a Shigella flexneri Y polysaccharide-mimetic peptide | Q36746947 | ||
| Clinical trials of Shigella vaccines: two steps forward and one step back on a long, hard road | Q36844719 | ||
| Induction of anti-carbohydrate antibodies by phage library-selected peptide mimics | Q36890938 | ||
| The elucidation of the structure of the core part of the LPS from Plesiomonas shigelloides serotype O17 expressing O-polysaccharide chain identical to the Shigella sonnei O-chain | Q36993963 | ||
| Shigellosis: the current status of vaccine development | Q37151797 | ||
| Mucosal adjuvanticity of a Shigella invasin complex with dna-based vaccines | Q37156758 | ||
| Synthesis, characterization, and immunogenicity in mice of Shigella sonnei O-specific oligosaccharide-core-protein conjugates | Q37194696 | ||
| Vaccination against shigellosis: is it the path that is difficult or is it the difficult that is the path? | Q37232206 | ||
| Iron and virulence in Shigella | Q38699506 | ||
| Vaccines against cholera, typhoid fever and shigellosis for developing countries | Q39217803 | ||
| Concentration of milk secretory immunoglobulin A against Shigella virulence plasmid-associated antigens as a predictor of symptom status in Shigella-infected breast-fed infants | Q39232647 | ||
| Field trial of a locally produced, killed, oral cholera vaccine in Vietnam | Q39439547 | ||
| Isolation and characterization of a Shigella flexneri invasin complex subunit vaccine | Q39517102 | ||
| Deoxycholate interacts with IpaD of Shigella flexneri in inducing the recruitment of IpaB to the type III secretion apparatus needle tip. | Q39627554 | ||
| Human monocytes kill Shigella flexneri but then die by apoptosis associated with suppression of proinflammatory cytokine production | Q39655437 | ||
| Intracellular type III secretion by cytoplasmic Shigella flexneri promotes caspase-1-dependent macrophage cell death | Q40085811 | ||
| Immunogenicity and efficacy of highly purified invasin complex vaccine from Shigella flexneri 2a. | Q40123700 | ||
| Supramolecular structure of the Shigella type III secretion machinery: the needle part is changeable in length and essential for delivery of effectors | Q40392389 | ||
| Future vaccine development at NICHD. | Q40429740 | ||
| Safety and immunogenicity of an oral, inactivated, whole-cell vaccine for Shigella sonnei: preclinical studies and a Phase I trial | Q40501431 | ||
| Semiquantitative estimation of Shigella antigen-specific antibodies: correlation with disease severity during shigellosis | Q41490859 | ||
| Interaction of Ipa proteins of Shigella flexneri with alpha5beta1 integrin promotes entry of the bacteria into mammalian cells | Q41491681 | ||
| Shigella flexneri induces apoptosis in infected macrophages | Q41614246 | ||
| Macrophage apoptosis in microbial infections. | Q41757390 | ||
| IpaD localizes to the tip of the type III secretion system needle of Shigella flexneri | Q41856079 | ||
| ShiA abrogates the innate T-cell response to Shigella flexneri infection | Q42079929 | ||
| Liposomes recruit IpaC to the Shigella flexneri type III secretion apparatus needle as a final step in secretion induction. | Q42128361 | ||
| Microbial pattern recognition receptors mediate M-cell uptake of a gram-negative bacterium | Q43181639 | ||
| A synthetic carbohydrate-protein conjugate vaccine candidate against Shigella flexneri 2a infection | Q43461979 | ||
| Cytotoxicity and interleukin-1beta processing following Shigella flexneri infection of human monocyte-derived dendritic cells | Q43974860 | ||
| Shigella effector IpaH9.8 binds to a splicing factor U2AF(35) to modulate host immune responses | Q44053369 | ||
| A novel caspase-1/toll-like receptor 4-independent pathway of cell death induced by cytosolic Shigella in infected macrophages | Q44118567 | ||
| Preparation of synthetic glycoconjugates as potential vaccines against Shigella flexneri serotype 2a disease | Q44891342 | ||
| P433 | issue | 12 | |
| P304 | page(s) | 1693-1704 | |
| P577 | publication date | 2009-12-01 | |
| P1433 | published in | Expert Review of Vaccines | Q15756339 |
| P1476 | title | Inactivated and subunit vaccines to prevent shigellosis | |
| P478 | volume | 8 |
| Q57929967 | A Novel Proteome Microarray Discriminates Targets of Human Antibody Reactivity following Oral Vaccination and Experimental Challenge |
| Q57170680 | A Phase I trial to evaluate the safety and immunogenicity of WRSs2 and WRSs3; two live oral candidate vaccines against Shigella sonnei |
| Q85333357 | A novel protein-based subunit Shigella vaccine candidate |
| Q38284501 | An assessment of enterotoxigenic Escherichia coli and Shigella vaccine candidates for infants and children |
| Q37965727 | Bacterial ghosts as carriers of protein subunit and DNA-encoded antigens for vaccine applications |
| Q34534027 | Causative species and serotypes of shigellosis in mainland China: systematic review and meta-analysis |
| Q34712010 | Changing emergence of Shigella sero-groups in Bangladesh: observation from four different diarrheal disease hospitals |
| Q92801042 | Characterization and immunogenicity of a Shigella flexneri 2a O-antigen bioconjugate vaccine candidate |
| Q35896237 | Combination vaccines against diarrheal diseases |
| Q38305664 | Comparison of resistance to third-generation cephalosporins in Shigella between Europe-America and Asia-Africa from 1998 to 2012. |
| Q37643320 | Development and preclinical evaluation of a trivalent, formalin-inactivated Shigella whole-cell vaccine. |
| Q37032264 | Evaluation of immunogenicity and protective efficacy of orally delivered Shigella type III secretion system proteins IpaB and IpaD. |
| Q36764372 | Evaluation of the Safety, Tolerability, and Immunogenicity of an Oral, Inactivated Whole-Cell Shigella flexneri 2a Vaccine in Healthy Adult Subjects |
| Q28728768 | High yield production process for Shigella outer membrane particles |
| Q38648043 | In silico analysis to identify vaccine candidates common to multiple serotypes of Shigella and evaluation of their immunogenicity. |
| Q37720658 | Intradermal delivery of Shigella IpaB and IpaD type III secretion proteins: kinetics of cell recruitment and antigen uptake, mucosal and systemic immunity, and protection across serotypes |
| Q57927103 | Morbidity and mortality due to shigella and enterotoxigenic Escherichia coli diarrhoea: the Global Burden of Disease Study 1990-2016 |
| Q84938205 | Mucosal immunization with Shigella flexneri outer membrane vesicles induced protection in mice |
| Q39416800 | Multi-serotype outer membrane vesicles of Shigellae confer passive protection to the neonatal mice against shigellosis |
| Q43623067 | Nanoparticle-based vaccine for mucosal protection against Shigella flexneri in mice |
| Q54227038 | Outer membrane vesicles for vaccination and targeted drug delivery. |
| Q35924773 | Production of a Shigella sonnei Vaccine Based on Generalized Modules for Membrane Antigens (GMMA), 1790GAHB |
| Q46677252 | Protective immunity by oral immunization with heat-killed Shigella strains in a guinea pig colitis model |
| Q90246288 | Recent Advances in the Synthesis of Glycoconjugates for Vaccine Development |
| Q38068954 | Recent progress towards development of a Shigella vaccine |
| Q38665950 | Safety Profile and Immunologic Responses of a Novel Vaccine Against Shigella sonnei Administered Intramuscularly, Intradermally and Intranasally: Results From Two Parallel Randomized Phase 1 Clinical Studies in Healthy Adult Volunteers in Europe. |
| Q37477196 | Safety and Immunogenicity of a Candidate Bioconjugate Vaccine against Shigella flexneri 2a Administered to Healthy Adults: a Single-Blind, Randomized Phase I Study. |
| Q84554549 | Safety and immunogenicity of a Shigella flexneri 2a Invaplex 50 intranasal vaccine in adult volunteers |
| Q84592118 | Safety and immunogenicity of an intranasal Shigella flexneri 2a Invaplex 50 vaccine |
| Q36981626 | Self-adjuvanting bacterial vectors expressing pre-erythrocytic antigens induce sterile protection against malaria |
| Q37477191 | Shigella Vaccine Development: Finding the Path of Least Resistance |
| Q36920244 | Shigella antigen-specific B memory cells are associated with decreased disease severity in subjects challenged with wild-type Shigella flexneri 2a. |
| Q24600679 | Shigella sonnei genome sequencing and phylogenetic analysis indicate recent global dissemination from Europe |
| Q43432983 | Shigella sonnei vaccine candidates WRSs2 and WRSs3 are as immunogenic as WRSS1, a clinically tested vaccine candidate, in a primate model of infection. |
| Q37778261 | Shigellosis update: advancing antibiotic resistance, investment empowered vaccine development, and green bananas. |
| Q34518265 | Status of vaccine research and development for Shigella |
| Q87419447 | Towards a non-living vaccine against Shigella flexneri: from the inactivation procedure to protection studies |
| Q46354821 | Two live attenuated Shigella flexneri 2a strains WRSf2G12 and WRSf2G15: a new combination of gene deletions for 2nd generation live attenuated vaccine candidates |
Search more.